AbbVie Inc. $ABBV Shares Bought by Meadowbrook Wealth Management LLC

Meadowbrook Wealth Management LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 16.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,184 shares of the company’s stock after acquiring an additional 2,130 shares during the quarter. AbbVie makes up 4.2% of Meadowbrook Wealth Management LLC’s holdings, making the stock its 5th biggest holding. Meadowbrook Wealth Management LLC’s holdings in AbbVie were worth $3,972,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Burk Holdings LLC bought a new position in AbbVie during the 2nd quarter worth approximately $30,000. Abound Financial LLC acquired a new position in shares of AbbVie in the 4th quarter worth approximately $32,000. Merkkuri Wealth Advisors LLC bought a new stake in shares of AbbVie in the 1st quarter valued at $34,000. Marquette Asset Management LLC increased its position in shares of AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the period. Finally, Phillip James Consulting Co. acquired a new stake in shares of AbbVie during the fourth quarter worth $36,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Up 0.3%

NYSE:ABBV traded up $0.84 during trading hours on Thursday, reaching $272.20. The company had a trading volume of 5,492,274 shares, compared to its average volume of 6,424,160. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $274.94. The firm has a market cap of $480.92 billion, a price-to-earnings ratio of 76.89, a P/E/G ratio of 1.22 and a beta of 0.24. The business’s 50-day simple moving average is $258.27 and its two-hundred day simple moving average is $235.87.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations bolster oncology prospects. AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400), a c-Met-directed antibody-drug conjugate, received two FDA Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory review while supporting the value of AbbVie’s growing ADC portfolio. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data adds another potential growth driver. AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result could expand Epkinly’s commercial opportunity if confirmed and approved. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Analysts raised their valuation estimates. JPMorgan increased its AbbVie price target to $300 from $285 and maintained an “overweight” rating. Cantor Fitzgerald also raised its target to $290 from $285 and assigned an “overweight” rating, signaling continued confidence in the company’s pipeline and earnings outlook.
• Neutral Sentiment: Recent operating momentum provides support: AbbVie’s latest reported revenue rose 10.2% year over year to $16.99 billion, while EPS exceeded consensus estimates. However, the stock’s elevated valuation—approximately 77 times earnings—leaves less room for disappointment.
• Negative Sentiment: Dividend sustainability remains a risk. Commentary highlighted a reported payout ratio above 190%, meaning dividends substantially exceed GAAP earnings. Although noncash items and adjusted earnings can distort this measure, investors may remain concerned about long-term dividend coverage and financial flexibility.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ABBV. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Canaccord Genuity Group increased their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. Morgan Stanley boosted their price objective on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Barclays upped their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $276.64.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.